CG Oncology (CGON) Cash from Financing Activities (2023 - 2026)

CG Oncology has reported Cash from Financing Activities for 4 years, with the latest figure at $393.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 87232.89% year-over-year to $393.0 million; the trailing twelve-month figure through Mar 2026 stood at $546.1 million (up 141.58% YoY), and the FY2025 full-year result was $153.6 million, down 75.55% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $393.0 million, up from $99.1 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $402.7 million in Q1 2024, with the low at -$15.2 million in Q2 2023.
• Historically, Cash from Financing Activities has averaged $97.1 million across 4 years, with a median of $2.2 million in 2024.
• Annual changes were most pronounced in 2025 — Cash from Financing Activities sank 840.0% — and 2026, when it soared 87232.89%.
• CG Oncology's Cash from Financing Activities stood at -$2.9 million in 2023, then jumped by 7814.57% to $223.4 million in 2024, then plunged by 55.66% to $99.1 million in 2025, then soared by 296.7% to $393.0 million in 2026.
• The last three Cash from Financing Activities figures came in at $393.0 million (Q1 2026), $99.1 million (Q4 2025), and $54.4 million (Q3 2025), per Business Quant data.